NEC member Abiomed has purchased a healthcare startup based in Maryland to expand its existing medical devices.
Breethe originally operated out of the University of Maryland Medical Center. Now a subsidiary of Abiomed, Breethe produces artificial lung treatments that allow for patients to move around more quickly and without need for oxygen tanks. The new technology will complement Abiomed’s existing portfolio of heart pumps and aims to improve patient outcomes.
“This acquisition aligns with our principles of leading in technology and innovation, putting patients first and striving to continually improve outcomes,” said Michael R. Minogue, Abiomed’s Chairman, President and CEO. “Physicians have asked Abiomed to bring this technology into our portfolio because of our ability to support patients, teach best practices, and collect critical data for research. This technology will allow us to treat cardiogenic shock patients who are already being supported, add pediatric offerings and treat a new patient population with respiratory failure.”
The Council commends Abiomed for continuing to lead in the field of healthcare technology to better serve and care for its patients. The Boston Business Journal and Abiomed report.
Recently from the Blog
November 24 Weekly Round-Up: NEC Members Contribute to COVID-19 Crisis Response